Implication of CYP24A1 Splicing in Breast Cancer

被引:12
|
作者
Scheible, Chimi [1 ]
Thill, Marc [2 ]
Baum, Sascha [3 ]
Solomayer, Erich [3 ]
Friedrich, Michael [1 ]
机构
[1] Helios Klinikum Krefeld, Klin Frauenheilkunde & Geburtshilfe, D-47805 Krefeld, Germany
[2] Agaples Markus Krankenhaus, Klin Frauenheilkunde & Geburtshilfe, D-60431 Frankfurt, Germany
[3] Univ Klinikum Saarlandes, Klin Frauenheilkunde & Geburtshilfe, D-66424 Homburg, Germany
关键词
Vitamin D-3; 24-hydroxylase; splicing variants; MCF-7; MCF-10; breast tissue; VITAMIN-D; D-3; 1,25-DIHYDROXYVITAMIN-D; METABOLISM; MECHANISM; VARIANTS; RISK; D-3-1-ALPHA-HYDROXYLASE; EXPRESSION; GROWTH;
D O I
10.2174/18715206113139990311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of CYP27B1 or vitamin D 1 alpha-hydroxylase (1 alpha-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1 alpha,25-dihydroxyvitamin D [1 alpha,25(OH)(2)D-3], alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues. Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression. In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa. The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa. Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 50 条
  • [1] CYP24A1 polymorphisms and breast cancer risk
    Beuy Joob
    Viroj Wiwanitkit
    [J]. Breast Cancer Research and Treatment, 2020, 180 : 525 - 525
  • [2] CYP24A1 polymorphisms and breast cancer risk
    Joob, Beuy
    Wiwanitkit, Viroj
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 525 - 525
  • [3] Targeting CYP24A1
    Susan J. Allison
    [J]. Nature Reviews Nephrology, 2016, 12 (4) : 196 - 196
  • [4] The Vitamin D/CYP24A1 Story in Cancer
    King, Amanda N.
    Beer, David G.
    Christensen, Paul J.
    Simpson, Robert U.
    Ramnath, Nithya
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (03) : 213 - 224
  • [5] Role and regulation of CYP24A1 in endometrial cancer
    Bokhari, Amber A.
    Lee, Laura R.
    Dewayne, Raboteau
    Hamilton, Chad A.
    Maxwell, George L.
    Rodriguez, Gustavo C.
    Syed, Vigar
    [J]. CANCER RESEARCH, 2015, 75
  • [6] CYP24A1 as a Potential Target for Cancer Therapy
    Sakaki, Toshiyuki
    Yasuda, Kaori
    Kittaka, Atsushi
    Yamamoto, Keiko
    Chen, Tai C.
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (01) : 97 - 108
  • [7] Low CYP24A1 mRNA expression and its role in prognosis of breast cancer
    Hongqiao Cai
    Yan Jiao
    Yanqing Li
    Zhaoying Yang
    Miao He
    Yahui Liu
    [J]. Scientific Reports, 9
  • [8] Low CYP24A1 mRNA expression and its role in prognosis of breast cancer
    Cai, Hongqiao
    Jiao, Yan
    Li, Yanqing
    Yang, Zhaoying
    He, Miao
    Liu, Yahui
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] CYP24A1 and kidney disease
    Petkovich, Martin
    Jones, Glenville
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (04): : 337 - 344
  • [10] Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer
    Voutsadakis, Ioannis A.
    [J]. MOLECULAR BIOLOGY REPORTS, 2020, 47 (12) : 9821 - 9830